Where Can You Report Your Adverse Drug Reactions Or Adverse Events Following Immunization

اين يمكنك التبليغ عن الاحداث الجانية للأدوية واللقاحات

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.

How to report

You can send the case reports using the following tools:

For Healthcare Professionals and the Public

The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.

The VigiMobile e-Form and e-Reporting e-Form:

The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones

Scan the QR Code by pressing the link
Click the three dots in the top-right corner
Choose Install app
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Apple IOS Phones

Scan the QR Code by pressing the link
Click on the share button
Add VigiMobile to the home screen
VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows

Press on the link
Install from the Browser menu
VigiMobile e-Form/e-Reporting e-Form is now installed

Scan QR Codes to Report:

ADRs Following Medication Use	AEFIs Following Vaccine Use

Or use the following link: LNPVP: e-Reporting eForm	Or use the following link: LNPVP: VigiMobile eForm

Direct Contact with the Lebanese National Pharmacovigilance Program:

You may contact the Lebanese National Pharmacovigilance Program through:

Email Address:

pv@moph.gov.lb, pv.moph@gmail.com

Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254

For Market Authorization Holders:

Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.

As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
L04AA27	SCLEMOD	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule	L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	133,856 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	149,393 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	163,184 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	176,974 L.L
B05XA03	SODIUM CHLORIDE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	161,805 L.L
B05XA03	SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%	0.45%	Injectable solution	161,314 L.L
B05XA03	SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%	0.45%	Injectable solution	149,393 L.L
B05XA03	SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%	0.45%	Injectable solution	148,566 L.L
B05XA03	SOLUFLEX SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%	0.45%	Injectable solution	176,974 L.L
H01CB05	SIGNIFOR	B	Pasireotide (diaspartate) - 0.3mg/ml	0.3mg/ml	Injectable solution	175,400,801 L.L
N04BC05	SIFROL ER	B	Pramipexole (dihydrochloride monohydrate) - 0.375mg	0.375mg	Tablet, extended release	473,033 L.L
D10AX03	SKINOREN	B	Azelaic acid - 0.2g/g	0.2g/g	Cream	722,987 L.L
H01CB02	SANDOSTATIN	B	Octreotide - 0.1mg/ml	0.1mg/ml	Injectable solution	1,038,790 L.L
N04BC05	SIFROL	B	Pramipexole (dihydrochloride monohydrate) - 0.18mg	0.18mg	Tablet	631,606 L.L
M01AE03	SOLKET INFLAMMATION AND PAIN	G	Ketoprofen Lysine salt - 0.16%	0.16%	Spray	946,065 L.L
B05XA05	SULFATE DE MAGNESIUM PROAMP	G	Magnesium sulfate - 0.15g/ml	0.15g/ml	Injectable solution	1,400,284 L.L
R01AD09	SINOCORT METERED DOSE	G	Mometasone furoate - 0.05%	0.05%	Spray, suspension	419,279 L.L
A06AD61	SOFLAX	G	Lactose - less than 6g/100ml, Galactose - less than 11g/100ml, Lactulose - 67g/100ml		Solution	258,018 L.L
R05C	SULDEX	G	Caffein anyhdrous - 0.216g, Antipyrine - 0.972g, Potassium sulfaguaiacolate - 1.44g		Syrup	152,302 L.L
A06AX01	SUPPOSITOIRE GLYCERINE ENFANT	G	Glycerol Stearate USP -		Suppository	179,179 L.L
A06AX01	SUPPOSITOIRE GLYCERINE ENFANT	G	Glycerol Stearate USP -		Suppository	179,179 L.L
A06AX01	SUPPOSITOIRE GLYCERINE ADULTE	G	Glycerol Stearate USP -		Suppository	179,179 L.L
N07BC51	SUBOXONE	G	Buprenorphine HCl - 2mg, Naloxone HCl - 0.5mg		Tablet, sublingual	1,473,590 L.L
N07BC51	SUBOXONE	G	Buprenorphine HCl - 8mg, Naloxone HCl - 2mg		Tablet, sublingual	7,382,584 L.L
N07BC51	SUBOXONE	G	Buprenorphine HCl - 16mg, Naloxone HCl - 4mg		Tablet, sublingual	14,284,125 L.L
A10BJ06	SEMATIDE	G	Semaglutide - 0.25mg & 0.5mg		Injectable solution	9,288,397 L.L
N01AB07	SUPRANE (DESFLURANE, USP)	B	Desflurane -		Inhalation	9,371,654 L.L
N01AB08	SEVOFLURANE	B	Sevoflurane -		Inhalation	12,327,290 L.L
S03AA30	SULFACHLOR	G	Sulfacetamide sodium - 110mg/ml, Chloramphenicol - 5mg/ml		Drops solution	202,216 L.L

...